EC authorises Sydnexis’ paediatric myopia treatment
Pharmaceutical Technology
JUNE 6, 2025
Founded in 2014, Sydnexis is a US-based company and has recently concluded the three-year primary endpoint of its Phase III trial of the low-dose atropine formulation. Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.
Let's personalize your content